Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials.

Author: ChenJian-Zhou, ChenQin-Hua, KangLi-Na, LiGuan-Nan, XieJun, XuBiao, ZhangXin-Lin, ZhuLi, ZhuQing-Qing

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Evolocumab and alirocumab were safe and well-tolerated, significantly reducing LDL-C by over 50%, increasing HDL-C, and resulting in favorable changes in other lipids.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) has been intensively studied to lower low-density lipoprotein cholesterol (LDL-C) levels. The purpose of this meta-analysis was to evaluate the safety and efficacy of anti-PCSK9 antibodies in randomized, controlled trial...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477483/

データ提供：米国国立医学図書館（NLM）

A Deep Dive into PCSK9 Inhibitors: A Meta-Analysis of 25 Randomized Controlled Trials

This research delves into the world of [cardiovascular health] by examining the safety and effectiveness of [PCSK9 antibodies] in lowering [LDL-C] levels. The study, conducted through a [meta-analysis] of [25 randomized controlled trials] involving [12,200] participants, employed a [rigorous methodology] to determine the impact of these antibodies on [lipid profiles] and overall health. This extensive analysis reveals crucial insights into the potential benefits and risks associated with these medications.

Safety and Efficacy of PCSK9 Antibodies: A Balancing Act

The findings suggest a generally positive safety profile for [evolocumab] and [alirocumab]. However, [alirocumab] demonstrated a slight increase in [injection-site reactions] while [evolocumab] was linked to a reduction in [abnormal liver function]. Both medications showed significant reductions in [LDL-C levels], exceeding [50%] in some cases, and demonstrated favorable changes in [HDL-C levels] as well.

PCSK9 Inhibitors: A Step Towards a Healthier Heart

The reduction in [LDL-C levels] brought about by these medications presents a significant opportunity for improving [cardiovascular health]. However, it's crucial to remember that [PCSK9 inhibitors] are not a magic bullet. As with any medication, these treatments should be considered in consultation with a healthcare professional, weighing the potential benefits against any potential risks. While this study sheds light on the promising aspects of these medications, further research is necessary to explore long-term outcomes and potential individual variations in response.

Dr. Camel's Conclusion

Imagine a camel traversing a vast desert, seeking the oasis of good health. These PCSK9 inhibitors are like those cool, refreshing waters, helping to quench the thirst for a healthier heart. While these medications offer a promising path, remember, as with any journey, it's essential to stay informed and consult a trusted guide – your doctor – to navigate the path safely and effectively.
Date :
  1. Date Completed 2015-12-30
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

26099511

DOI: Digital Object Identifier

PMC4477483

Related Literature

Article Analysis
・Effects of alirocumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.